Overview

Useful For
Evaluation of growth disorders
Evaluation of growth hormone deficiency or excess in children and adults
Monitoring of recombinant human growth hormone treatment
Follow-up of individuals with acromegaly and gigantism

Method Name
Liquid Chromatography-Mass Spectrometry (LC/MS)

NY State Available
Yes

Specimen

Specimen Type
Serum

Necessary Information
Indicate patient's age and sex.

Specimen Required
Container/Tube:
Preferred: Red top
Acceptable: Serum gel

Specimen Volume: 0.5 mL

Forms
If not ordering electronically, complete, print, and send a General Request (T239) with the specimen.

Specimen Minimum Volume
0.3 mL

Reject Due To

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemolysis</td>
<td>Mild OK; Gross reject</td>
</tr>
<tr>
<td>Lipemia</td>
<td>Mild OK; Gross OK</td>
</tr>
<tr>
<td>Icterus</td>
<td>Mild OK; Gross OK</td>
</tr>
<tr>
<td>Other</td>
<td>NA</td>
</tr>
</tbody>
</table>

Specimen Stability Information
**Clinical and Interpretive**

**Clinical Information**

Insulin-like growth factor 1 (IGF1) is a 70-amino acid polypeptide (molecular weight kDa; Uniprot Accession P05019 [aa 49-118]). IGF1 is a member of a family of closely related growth factors with high homology to insulin that signal through a corresponding group of highly homologous tyrosine kinase receptors. IGF1 is produced by many tissues, but the liver is the main source of circulating IGF1. IGF1 is the major mediator of the anabolic and growth-promoting effects of growth hormone (GH). IGF1 is transported by IGF-binding proteins, in particular insulin-like growth factor-binding protein 3 (IGFBP3), which also controls its bioavailability and half-life. Noncomplexed IGF1 and IGFBP3 have short half-lives (t1/2) of 10 and 30 to 90 minutes, respectively, while the IGFBP3/IGF1 complex is cleared with a much slower t1/2 of 12 hours.

The secretion patterns of IGF1 and IGFBP3 mimic each other, their respective syntheses being controlled by GH. Unlike GH secretion, which is pulsatile and demonstrates significant diurnal variation, IGF1 and IGFBP3 levels show only minor fluctuations. IGF1 and IGFBP3 serum levels, therefore, represent a stable and integrated measurement of GH production and tissue effect.

Low IGF1 and IGFBP3 levels are observed in GH deficiency or GH resistance. If acquired in childhood, these conditions result in short stature.

Childhood GH deficiency can be an isolated abnormality or associated with deficiencies of other pituitary hormones. Some of the latter cases may be due to pituitary or hypothalamic tumors, or result from cranial radiation or intrathecal chemotherapy for childhood malignancies.

Most GH resistance in childhood is mild-to-moderate, with causes ranging from poor nutrition to severe systemic illness (eg, renal failure). These individuals may have IGF1 and IGFBP3 levels within the reference range. Severe childhood GH resistance is rare and usually due to defects of the GH-receptor, its downstream signaling cascades, or deleterious mutations in IGF1, its binding proteins, or its receptor signaling cascades.

Both GH deficiency and mild-to-moderate GH resistance can be treated with recombinant human GH (rhGH) injections, while severe resistance will usually not respond to GH. However, such patients might respond to recombinant IGF1 therapy, unless the underlying defect is in the IGF1 receptor or its downstream signaling systems.

The exact prevalence and causes of adult GH resistance are uncertain, but adult GH deficiency is seen mainly in pituitary tumor patients. It is associated with decreased muscle bulk and increased cardiovascular morbidity and mortality, but replacement therapy remains controversial.

Elevated serum IGF1 and IGFBP3 levels often indicate a sustained overproduction of GH, or excessive rhGH therapy. Endogenous GH excess is caused mostly by GH-secreting pituitary adenomas, resulting in gigantism, if acquired before epiphyseal closure, and in acromegaly thereafter. Both conditions are associated with generalized organomegaly, hypertension, diabetes, cardiomyopathy, osteoarthritis, compression neuropathies, a mild increase in cancer risk (breast, colon, prostate, lung), and diminished longevity. It is plausible, but unproven, that long-term rhGH

<table>
<thead>
<tr>
<th>Specimen Type</th>
<th>Temperature</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum</td>
<td>Frozen (preferred)</td>
<td>28 days</td>
</tr>
<tr>
<td></td>
<td>Ambient</td>
<td>72 hours</td>
</tr>
<tr>
<td></td>
<td>Refrigerated</td>
<td>72 hours</td>
</tr>
</tbody>
</table>

Document generated September 19, 2019 at 11:40pm CDT
Overtreatment may result in similar adverse outcomes.

Malnutrition results in low serum IGF1 concentrations, which recover with restoration of adequate nutrition.

**Reference Values**

**Males:**

- 0-11 months: 18-156 ng/mL
- 1 year: 14-203 ng/mL
- 2 years: 16-222 ng/mL
- 3 years: 22-229 ng/mL
- 4 years: 30-236 ng/mL
- 5 years: 39-250 ng/mL
- 6 years: 47-275 ng/mL
- 7 years: 54-312 ng/mL
- 8 years: 61-356 ng/mL
- 9 years: 67-405 ng/mL
- 10 years: 73-456 ng/mL
- 11 years: 79-506 ng/mL
- 12 years: 84-551 ng/mL
- 13 years: 90-589 ng/mL
- 14 years: 95-618 ng/mL
- 15 years: 99-633 ng/mL
- 16 years: 104-633 ng/mL
- 17 years: 107-615 ng/mL
- 18-22 years: 91-442 ng/mL
- 23-25 years: 66-346 ng/mL
- 26-30 years: 60-329 ng/mL
- 31-35 years: 54-310 ng/mL
- 36-40 years: 48-292 ng/mL
41-45 years: 44-275 ng/mL
46-50 years: 40-259 ng/mL
51-55 years: 37-245 ng/mL
56-60 years: 34-232 ng/mL
61-65 years: 33-220 ng/mL
66-70 years: 32-209 ng/mL
71-75 years: 32-200 ng/mL
76-80 years: 33-192 ng/mL
81-85 years: 33-185 ng/mL
86-90 years: 33-179 ng/mL
>91 years: 32-173 ng/mL

Females:
0-11 months: 14-192 ng/mL
1 year: 23-243 ng/mL
2 years: 28-256 ng/mL
3 years: 31-249 ng/mL
4 years: 33-237 ng/mL
5 years: 36-234 ng/mL
6 years: 39-246 ng/mL
7 years: 44-279 ng/mL
8 years: 51-334 ng/mL
9 years: 61-408 ng/mL
10 years: 73-495 ng/mL
11 years: 88-585 ng/mL
12 years: 104-665 ng/mL
13 years: 120-719 ng/mL
Test Definition: IGFMS
IGF-1, LC/MS, S

14 years: 136-729 ng/mL
15 years: 147-691 ng/mL
16 years: 153-611 ng/mL
17 years: 149-509 ng/mL
18-22 years: 85-370 ng/mL
23-25 years: 73-320 ng/mL
26-30 years: 66-303 ng/mL
31-35 years: 59-279 ng/mL
36-40 years: 54-258 ng/mL
41-45 years: 49-240 ng/mL
46-50 years: 44-227 ng/mL
51-55 years: 40-217 ng/mL
56-60 years: 37-208 ng/mL
61-65 years: 35-201 ng/mL
66-70 years: 34-194 ng/mL
71-75 years: 34-187 ng/mL
76-80 years: 34-182 ng/mL
81-85 years: 34-177 ng/mL
86-90 years: 33-175 ng/mL
> or =91 years: 25-179 ng/mL

Tanner Stage reference ranges:

Males
Stage I: 81-255 ng/mL
Stage II: 106-432 ng/mL
Stage III: 245-511 ng/mL
Stage IV: 223-578 ng/mL
Test Definition: IGFMS

IGF-1, LC/MS, S

Stage V: 227-518 ng/mL

Females
Stage I: 86-323 ng/mL
Stage II: 118-451 ng/mL
Stage III: 258-529 ng/mL
Stage IV: 224-586 ng/mL
Stage V: 188-512 ng/mL


Note: Puberty onset (transition from Tanner stage I to Tanner stage II) occurs for boys at a median age of 11.5 (+/- 2) years and for girls at a median age of 10.5 (+/- 2) years. There is evidence that it may occur up to 1 year earlier in obese girls and in African American girls. For boys, there is no definite proven relationship between puberty onset and body weight or ethnic origin. Progression through Tanner stages is variable. Tanner stage V (young adult) should be reached by age 18.

Interpretation

Both insulin-like growth factor 1 (IGF1) and insulin-like growth factor-binding protein 3 (IGFBP3) measurements can be used to assess growth hormone (GH) excess or deficiency. However, for all applications, IGF1 measurement has generally been shown to have superior diagnostic sensitivity and specificity, and should be used as the primary test. In particular, in the diagnosis and follow-up of acromegaly and gigantism, IGFBP3 measurement adds little if anything to IGF1 testing.

The combination of IGF1 and IGFBP3 measurements might offer some benefits over either analyte alone in the diagnosis of GH deficiency and resistance, and in the monitoring of recombinant human GH (rhGH) therapy.

Serum IGF1 and IGFBP3 concentrations below the 2.5th percentile (Standard deviation score, Z-score of <-2) for age are consistent with GH deficiency or severe GH resistance, but patients with incomplete GH deficiency or mild-to-moderate GH resistance may have levels within the reference range. In GH deficiency, GH levels may also be low and can show suboptimal responses in stimulation tests (e.g., exercise, clonidine, arginine, ghrelin, growth hormone-releasing hormone, insulin-induced hypoglycemia), while in severe GH resistance, GH levels might be substantially elevated. However, dynamic GH testing is not always necessary for diagnosis. If it is undertaken, it should be performed and interpreted in endocrine testing centers under the supervision of a pediatric or adult endocrinologist.

The aim of both pediatric and adult GH replacement therapy is to achieve IGF1 and IGFBP3 levels within the reference range, ideally within the middle-to-upper third. Higher levels are rarely associated with any further therapeutic gains, but could potentially lead to long-term problems of GH excess.

Elevated IGF1 and IGFBP3 levels support the diagnosis of acromegaly or gigantism in individuals with appropriate symptoms or signs. In successfully treated patients, both levels should be within the normal range, ideally within the lower third. In both diagnosis and follow-up, IGF1 levels correlate better with clinical disease activity than IGFBP3 levels.

After transsphenoidal removal of pituitary tumors in patients with acromegaly, IGF-I concentration starts to decrease and returns to normal levels in most patients postoperatively by the fourth day.
Persons with anorexia or malnutrition have low values of IGF1. IGF1 is a more sensitive indicator than prealbumin, retinol-binding protein, or transferrin for monitoring nutritional repletion.

Cautions

Insulin-like growth factor 1 (IGF1) and insulin-like growth factor-binding protein 3 (IGFBP3) reference ranges are highly age dependent and results must always be interpreted within the context of the patient's age.

During normal pregnancy, serum IGF1 increases on average almost 2-fold (range approximately 1.1-fold to approximately 4-fold) over prepregnancy baseline concentrations; however, reference ranges on this population have not been formally established in our institution.

Discrepant IGF1 and IGFBP3 results can sometimes occur due to liver and kidney disease; however, this is uncommon and such results should alert laboratories and physicians to the possible occurrence of a preanalytical or analytical error.

Currently, IGF1 or IGFBP3 IGF1 cannot be reliably used as risk indicators or prognostic markers in breast, colon, prostate, or lung cancer.

IGF1 assays exhibit significant variability among platforms and manufacturers. Direct comparison of results obtained by different assays is problematic. If IGF1 and IGFBP3 are being used for serial monitoring, rebaselining of patients is preferred if assays are changed.

Several amino acid polymorphisms within IGF1 have been discovered. At least 4 of these are known to result in IGF1 isoforms with diminished biological activity. IGF1 immunoassays vary in their ability to detect these reduced-function mutants. If they do detect the mutants, then this will result in an overestimation of functionally active IGF1 in an affected patient. By contrast, mass spectrometry (MS)-based IGF1 assay can usually selectively detect the active IGF1 isoforms. However, there might be as yet unknown functionally different variants of IGF1, which even MS cannot distinguish from wild-type (normal) IGF1.

Supportive Data

The IDS automated immunoassay showed a consistent 10% to 20% high bias in comparison to the mass spectrometry assay for insulin-growth factor 1 (IGF1). New reference ranges were calculated for the mass spectrometry assay using 7,325 specimens, including 224 Tanner-staged pediatric samples.

Clinical Reference


Performance

Method Description
Stable isotope labeled internal standard is added to patient samples. IGF-1 is then extracted by selective precipitation. The extracted samples are analyzed by liquid chromatography-mass spectrometry (LC/MS). This is a Laboratory-developed mass spectrometry test, calibrated against the 1st WHO International standard for Insulin-like growth factor-1 (92/254).(Unpublished Mayo method)

PDF Report
No

Day(s) and Time(s) Test Performed
Monday through Friday, Sunday; 12 p.m.

Analytic Time
2 days

Maximum Laboratory Time
3 days

Specimen Retention Time
3 months

Performing Laboratory Location
Rochester

Fees and Codes

Fees
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information
84305

LOINC® Information

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Test Order Name</th>
<th>Order LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>IGFMS</td>
<td>IGF-1, LC/MS, S</td>
<td>2484-4</td>
</tr>
</tbody>
</table>

Document generated September 19, 2019 at 11:40pm CDT
<table>
<thead>
<tr>
<th>Result ID</th>
<th>Test Result Name</th>
<th>Result LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>62750</td>
<td>IGF-1, LC/MS, S</td>
<td>2484-4</td>
</tr>
<tr>
<td>35781</td>
<td>Z-score</td>
<td>73561-3</td>
</tr>
</tbody>
</table>